Demand for excipients to rise; TheraBiogen launches migraine nasal spray;

> In one measure of the increasing importance of drug delivery, the U.S. demand for excipients will rise 3.9 percent a year to $1.9 billion in 2015. Excipients can, among other things, control the release of medication. Story

> TheraBiogen has launched a nasal spray for migraine relief. Item

> Biogen Idec has obtained the European Commission's approval for its Avonex Pen for patients who are suffering from relapsing multiple sclerosis. Avonex Pen is a single-use, once-a-week, intramuscular autoinjector. The needle is hidden prior to injection. More here

> Helicon Group's electronic drug delivery device for syringes successful in tests. Article